FDA's Phil Frappaolo
This article was originally published in The Gray Sheet
Executive Summary
Deputy director of the Center for Devices and Radiological Health's Office of Compliance will take up a new post in the CDRH director's office overseeing implementation of the device center's "strategic vision" (1"The Gray Sheet" Oct. 23, 2000, p. 13). Frappaolo has served as compliance deputy director since November 1992 and has been co-czar of CDRH's "reengineering" initiative since the program was launched in early 1997. Office of Compliance In Vitro Diagnostics Devices Branch Chief Betty Collins will serve the first of two 60-day details to fill the vacant deputy director post, followed by OC Special Assistant Casper Uldriks
You may also be interested in...
CDRH's "Strategic Vision" Captures Unique Device Industry Landscape
The Center for Devices and Radiological Health's strategic vision for the next five years will replace the linear premarket/postmarket approach to device regulation with a more holistic program.
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.